Ken Griffin Adc Therapeutics Sa Transaction History

Citadel Advisors LLC

$618 Billion
Q3 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Citadel Advisors LLC holds 820,715 shares of ADCT stock, worth $3.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

820,715

Previous 38,000 2059.78%

Holding current value

$3.25 Million

Previous $101,000 3149.5%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$2.64 - $4.02 $2.09 Million - $3.18 Million	791,709 Added 2729.47%	820,715 $3.28 Million
Q2 2025 Aug 14, 2025	BUY	$1.1 - $3.67 $31,906 - $106,452	29,006 New	29,006 $77,000
Q2 2024 Aug 14, 2024	SELL	$2.55 - $5.09 $2.32 Million - $4.64 Million	-911,031 Reduced 95.65%	41,433 $130,000
Q1 2024 May 15, 2024	SELL	$1.66 - $5.29 $1.5 Million - $4.77 Million	-900,948 Reduced 48.61%	952,464 $4.28 Million
Q4 2023 Feb 14, 2024	SELL	$0.47 - $1.79 $491,013 - $1.87 Million	-1,044,709 Reduced 36.05%	1,853,412 $3.08 Million

Q3 2023 Nov 14, 2023	SELL	$0.72 - $2.37 $195,644 - $643,995	-271,728 Reduced 8.57%	2,898,121 $2.61 Million
Q2 2023 Aug 14, 2023	SELL	$1.9 - $2.66 $374,024 - $523,634	-196,855 Reduced 5.85%	3,169,849 $6.82 Million
Q1 2023 May 15, 2023	BUY	$1.92 - $5.45 $2.65 Million - $7.51 Million	1,378,836 Added 69.36%	3,366,704 $6.57 Million
Q4 2022 Feb 14, 2023	BUY	$2.87 - $5.24 $5.59 Million - $10.2 Million	1,948,077 Added 4895.77%	1,987,868 $7.63 Million
Q3 2022 Nov 14, 2022	BUY	$4.66 - $10.31 $185,426 - $410,245	39,791 New	39,791 $192,000
Q3 2021 Nov 15, 2021	SELL	$20.45 - $30.0 $95,153 - $139,590	-4,653 Reduced 19.39%	19,346 $525,000
Q2 2021 Aug 16, 2021	BUY	$20.38 - $27.04 $180,098 - $238,952	8,837 Added 58.28%	23,999 $584,000
Q1 2021 May 17, 2021	SELL	$22.75 - $34.05 $1.59 Million - $2.37 Million	-69,736 Reduced 82.14%	15,162 $370,000
Q4 2020 Feb 16, 2021	BUY	$25.26 - $38.02 $2.14 Million - $3.23 Million	84,898 New	84,898 $2.72 Million
Q3 2020 Nov 16, 2020	SELL	$32.87 - $51.05 $977,488 - $1.52 Million	-29,738 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$29.65 - $46.81 $881,731 - $1.39 Million	29,738 New	29,738 $1.39 Million

Others Institutions Holding ADCT

# of Institutions

108

Shares Held

67.3M

Call Options Held

39.8K

Put Options Held

68.4K

View Full List

About ADC Therapeutics SA

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $307M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

More about ADCT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account